Pretreatment anemia is associated with poorer survival in patients with stage I and II gastric cancer

Jian Guo Shen, Jae Ho Cheong, Woo Jin Hyung, Junuk Kim, Seung Ho Choi, Sung Hoon Noh

Research output: Contribution to journalReview article

29 Citations (Scopus)

Abstract

Background and Objectives: A negative correlation between anemia and outcome has been demonstrated in various cancers treated with radiotherapy. However, it is rarely studied whether this correlation may exist in surgical setting. Our aim was to investigate the relationship between pretreatment anemia and survival in surgically treated patients with gastric cancer. Methods: A total of 1,688 patients who had undergone curative resection for gastric cancer between 1991 and 1995 were reviewed. Anemia was defined as a hemoglobin level <12.0 g/dl. The influence of anemia on patient overall survival was evaluated by univariate and multivariate analysis. Results: Pretreatment anemia was present in 39.9% of the patients. The 10-year overall survival rate in anemic patients was 48.2% as compared with 62.6% in nonanemic patients (P < 0.001). In subgroup analysis according to the stage, the significant difference in 10-year overall survival rate between anemic and nonanemic patients was found in stage I and II gastric cancer (76.1% vs. 83.5% in stage I, P = 0.030; 55.1% vs. 67.2% in stage II, P = 0.043). On multivariate analysis, anemia was an independent prognostic predictor in patients with stage I and II disease (P = 0.007; RR, 1.466; 95% CI, 1.109-1.937). Conclusions: Pretreatment anemia was found to have an independent relationship to the long-term survival of patients with stage I and II gastric cancer.

Original languageEnglish
Pages (from-to)126-130
Number of pages5
JournalJournal of surgical oncology
Volume91
Issue number2
DOIs
Publication statusPublished - 2005 Aug 1

All Science Journal Classification (ASJC) codes

  • Surgery
  • Oncology

Fingerprint Dive into the research topics of 'Pretreatment anemia is associated with poorer survival in patients with stage I and II gastric cancer'. Together they form a unique fingerprint.

  • Cite this